Results 171 to 180 of about 86,457 (338)

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, EarlyView.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

The Evolving Role of Alkylating Agents in Multiple Myeloma: From the Past and Present to Next-Generation Peptide Drug Conjugates

healthbook TIMES. Oncology Hematology
Despite significant recent advances in treatment with small molecules, inhibitor, antibodies and immunotherapy, multiple myeloma (MM) remains an incurable malignancy characterized by high rates of relapse. Alkylating agents, a cornerstone of MM treatment,
Yuxin Liu, Shahrier Hossain, Omar Nadeem, Shonali Midha, Monique Hartley-Brown, Taya Salman, Pedro Vianna, Adam S. Sperling, Giada Bianchi, Clifton Mo, Jacob Laubach, Paul G. Richardson   +11 more
doaj   +1 more source

alkylating agent

Citation: 'alkylating agent' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.15454 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

Reductive Amination of Ketones or Amination of Alcohols over Heterogeneous Cu Catalysts: Matching the Catalyst Support with the N‐Alkylating Agent [PDF]

, 2012
Federica Santoro, Rinaldo Psaro, Nicoletta Ravasio, Federica Zaccheria   +3 more
openalex   +1 more source

Alkylboronic acids as alkylating agents: photoredox-catalyzed alkylation reactions assisted by K₃PO₄. [PDF]

Chem Sci, 2022
Yue F, Ma H, Song H, Liu Y, Dong J, Wang Q.   +5 more
europepmc   +1 more source

From Light‐Driven to Dark Synthesis: Streamlining Perfluoroalkyl Selenide Ether Formation

European Journal of Organic Chemistry, EarlyView.
Two orthogonal and user‐friendly protocols enable the efficient construction of (Se/S)RF bonds from simple dichalcogenides and perfluoroalkyl iodides. Visible‐light irradiation at 395 nm promotes seleno‐ and thioether formation, while a dark KOH/MeCN variant delivers selenoethers in minutes. Both approaches operate under mild, metal‐ and photocatalyst‐
Loydel Torres Barroso, Romina S. Conde, Damian E. Yerien, Agustin A. Zottola, Al Postigo, Sebastian Barata‐Vallejo   +5 more
wiley   +1 more source

Self-Immolative System for Disclosure of Reactive Electrophilic Alkylating Agents: Understanding the Role of the Reporter Group. [PDF]

J Org Chem, 2021
Gavriel AG, Leroux F, Khurana GS, Lewis VG, Chippindale AM, Sambrook MR, Hayes W, Russell AT.   +7 more
europepmc   +1 more source

Interpretation of in vitro concentration‐response data for risk assessment and regulatory decision‐making: Report from the 2022 IWGT quantitative analysis expert working group meeting

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Quantitative risk assessments of chemicals are routinely performed using in vivo data from rodents; however, there is growing recognition that non‐animal approaches can be human‐relevant alternatives. There is an urgent need to build confidence in non‐animal alternatives given the international support to reduce the use of animals in toxicity ...
Marc A. Beal, Guangchao Chen, Kerry L. Dearfield, Min Gi, Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Alexandra S. Long, David P. Lovell, Barbara L. Parsons, Stefan Pfuhler, John Wills, Andreas Zeller, George Johnson, Paul A. White   +14 more
wiley   +1 more source

Alcohol and Head and Neck Cancer: Updates on the Role of Oxidative Stress, Genetic, Epigenetics, Oral Microbiota, Antioxidants, and Alkylating Agents. [PDF]

Antioxidants (Basel), 2022
Ferraguti G, Terracina S, Petrella C, Greco A, Minni A, Lucarelli M, Agostinelli E, Ralli M, de Vincentiis M, Raponi G, Polimeni A, Ceccanti M, Caronti B, Di Certo MG, Barbato C, Mattia A, Tarani L, Fiore M.   +17 more
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source